KATHRYN SYED: Open Payments
NPI 1700173440 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,978 in 117 payments from 16 companies in 2025. Trend: 2023 $2,763 · 2024 $2,407 · 2025 $1,978
Food & beverage: $1,978
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $320 |
| Alkermes, Inc. | 17 | $303 |
| Teva Pharmaceuticals USA, Inc. | 30 | $287 |
| Janssen Pharmaceuticals, Inc | 12 | $220 |
| Otsuka America Pharmaceutical, Inc. | 9 | $183 |
| E.R. Squibb & Sons, L.L.C. | 9 | $175 |
| ABBVIE INC. | 6 | $112 |
| AstraZeneca Pharmaceuticals LP | 5 | $88 |
| Braeburn Inc. | 3 | $66 |
| Indivior Inc. | 4 | $66 |
Products named: INGREZZA, INVEGA SUSTENNA, ARISTADA, UZEDY, COBENFY, VRAYLAR, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
